Cisen Pharmaceutical Co., Ltd. (SHA:603367)
China flag China · Delayed Price · Currency is CNY
14.91
+0.39 (2.69%)
Aug 20, 2026, 3:00 PM CST

Cisen Pharmaceutical Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
408.45421.25508.91521.34349.96334.15
Depreciation & Amortization
197.38197.38222.72233.89230.25219.49
Other Amortization
4.384.382.091.960.983.14
Loss (Gain) From Sale of Assets
0.710.710.14-0.59-0.97-0.27
Asset Writedown & Restructuring Costs
10.8510.85-3.5374.2713.0621.34
Loss (Gain) From Sale of Investments
-163.15-163.15-72.83-33.74-15.56-66.42
Provision & Write-off of Bad Debts
59.1359.1356.032.3416.46-5.92
Other Operating Activities
154.196.3612.4410.846.83-1.68
Change in Accounts Receivable
-102.24-102.24-20.82-336.44-542.34-113.29
Change in Inventory
178.69178.69-115.04-144.3118.1-14.81
Change in Accounts Payable
-144-1444.69118.51197.67-113.8
Change in Other Net Operating Assets
-9.34-9.34-25.94-4.92-18.73-9.26
Operating Cash Flow
601.4466.37570.85451.24258.35233.6
Operating Cash Flow Growth
56.89%-18.30%26.51%74.67%10.59%-45.80%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-63.18-64.76-101.81-17.71-35.19-51.02
Sale of Property, Plant & Equipment
2.063.360.490.760.010.49
Cash Acquisitions
---0.42--
Investment in Securities
-265.53-265.5316-408.36-274.13289.99
Other Investing Activities
-46.16153.1263.5746.7736.2388.02
Investing Cash Flow
-372.81-173.82-21.75-378.13-273.08327.48

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-12.0826.8730.98--
Long-Term Debt Issued
-15.3453.3354250138
Total Debt Issued
20.6427.4380.1984.98250138
Long-Term Debt Repaid
--73.33-137.25-59.05-232.43-340.24
Total Debt Repaid
-8.44-73.33-137.25-59.05-232.43-340.24
Net Debt Issued (Repaid)
12.2-45.9-57.0625.9317.57-202.24
Common Dividends Paid
-182.84-182.92-304.56-156.13-139.54-120.73
Other Financing Activities
-2.34-3.14-3.02-3.6230.164.54
Financing Cash Flow
-172.98-231.96-364.63-133.8108.19-318.43

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-2.17-0.790.360.650.65-0.22
Net Cash Flow
53.4459.8184.83-60.0494.11242.43

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
538.22401.61469.04433.53223.15182.58
Free Cash Flow Growth
82.10%-14.38%8.19%94.27%22.22%-20.18%
Free Cash Flow Margin
15.95%11.66%11.78%9.71%5.49%4.83%
Free Cash Flow Per Share
1.190.891.030.960.490.40
Levered Free Cash Flow
452.18499.95483.53443.54283.19137.89
Unlevered Free Cash Flow
452.91500.79487.87447.66285.87141.7

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
0.90.91.910.60.440.38
Cash Income Tax Paid
313.94334.19389.98433.03357.12390.99
Change in Working Capital
-70.55-70.55-155.1-359.05-342.66-270.23